Rater Training and COA Data Quality in a Phase 3 Neurology Trial

In complex neurology trials, variability in how assessors administer and score clinical outcome assessments can quietly undermine even the most rigorous study design. This case study examines how a global Phase 3 sponsor addressed that risk in a generalized myasthenia gravis trial, deploying Signant's specialized QMG scale certification, co-rating requirements, and blinded COA data analytics across more than 200 raters at 90 sites worldwide. The result was standardized, high-quality evidence that supported clinically meaningful findings and a clear path to regulatory submission.